# US 2026/0216245 A1 · Therapeutic base editing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216245 A1
- Document ID: US20260216245A1
- Status: Published application
- Kind: A1
- Application number: 19/151,579
- Filed: 2024-02-07
- Published: 2026-07-30
- Earliest claimed: 2023-02-07
- Assignees: The J. David Gladstone Institute, A Testamentary Trust Established Under the Will of J. David Gladst; The Regents of the University of California
- Applicants: The J. David Gladstone Institute, A Testamentary Trust Established Under the Will of J. David Gladst; The Regents of The University of California
- Inventors: Alexander Marson; Carl Ward; Ralf Schmidt
- Web page: https://patentgrep.com/patent/US20260216245A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4232: {Tumor necrosis factors [TNF] or CD70}
- A61K 40/4234: {Interleukins [IL]}
- A61K 40/4235: {Interferons [IFN]}
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 14/525: Tumour necrosis factor [TNF]
- C07K 14/55: IL-2
- C07K 14/57: IFN-gamma
- C07K 14/70521: {CD28, CD152}
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C12N 5/0636: {T lymphocytes}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 9/78: acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N 15/1093: {General methods of preparing gene libraries, not provided for in other subgroups}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/86: Viral vectors
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/80: acting on amide bonds in linear amides {(3.5.1)}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2510/00: Genetically modified cells
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2710/16043: viral genome or elements thereof as genetic vector
- C12N 2740/10043: viral genome or elements thereof as genetic vector
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12Y 305/04002: Adenine deaminase (3.5.4.2)
- C12Y 305/04005: Cytidine deaminase (3.5.4.5)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

A method to screen for base edited genes with modifications in therapeutic targets, cells produced by the method and methods of using the modified cells are provided.

## Claims

### Claim 1

A method comprising:
contacting human immune cells with one or more sgRNAs targeted to one or more coding regions in one or more genes and a base editor or nucleic acid encoding the base editor; and
selecting one or more human immune cells that have an altered immune cell activity and optionally sorting the immune cells based on the profile.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cells are T cells.

### Claim 3 (depends on 1)

The method of claim 1 wherein the human immune cells are contacted with a library of sgRNAs targeted to the one or more coding regions in a plurality of genes.

### Claim 4 (depends on 1)

The method of claim 1, wherein a library of viruses expresses the one or more sgRNAs.

### Claim 5 (depends on 1)

The method of claim 1, wherein a virus encodes the base editor.

### Claim 6 (depends on 1)

The method of claim 1, wherein the sgRNA and the nucleic acid encoding the base editor are on a different nucleic acid molecule.

### Claim 7 (depends on 4)

The method of claim 4, wherein the virus is a lentivirus, retrovirus, adenovirus, herpesvirus or adeno-associated virus.

### Claim 8 (depends on 1)

The method of claim 1, wherein the base editor comprises ABE or CBE.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the cells are selected for altered expression of TNFalpha, IL2 or IFNgamma, or any combination thereof.

### Claim 11 (depends on 1)

The method of claim 1, wherein the cells are sorted to separate cells that have altered expression of TNFalpha, IL2 or IFNgamma, or any combination thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein the cells are selected for altered expression of CD25 or PD1, or both.

### Claim 13 (depends on 1)

The method of claim 1, wherein the cells are sorted to separate cells that have altered expression of CD25 or PD1, or both, from cells that do not express CD25 and/or PDL.

### Claim 14 (depends on 1)

The method of claim 1, wherein the sgRNAs comprise a plurality of the sequences in FIG. 1B, 2B, 3B, 4B or 8 or a sequence with at least 85% nucleic acid sequence identity thereto.

### Claim 15 (depends on 1)

The method of claim 1, wherein the one or more coding regions that are altered are in one or more of the genes in FIG. 1A, 2A, 3A, 4A or 7 or have or are modified at a site in FIG. 1A, 2A, 3A, 4A, or 7 or a sequence with at least 85% nucleic acid sequence identity thereto.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

An isolated human cell selected by the method of claim 1.

### Claim 18

An isolated cell having a base edited gene in FIG. 1, 2, 3, 4 or 7 which alters one or more activities of the cell.

### Claim 19 (depends on 18)

The isolated cell of claim 18 which has increased T cell activity relative to a corresponding cell that lacks the base edited gene.

### Claim 20 (depends on 18)

The isolated cell of claim 18 which has decreased T cell activity relative to a corresponding cell that lacks the base edited gene.

### Claim 21

(canceled)

### Claim 22 (depends on 18)

The isolated cell of claim 18 which is modified at a site in FIG. 1A, 2A, 3A, 4A or 7 or a sequence with at least 85% nucleic acid sequence identity thereto.

### Claim 23 (depends on 18)

A method to prevent, inhibit or treat cancer is a mammal, comprising administering to the mammal a composition having a plurality of the isolated cells of claim 18.

### Claim at position 24

-26. (canceled)

### Claim 27 (depends on 23)

The method of claim 23, wherein the cancer is a sarcoma, lymphoma, melanoma, or carcinoma, or is lung cancer, breast cancer, prostate cancer, pancreatic cancer or ovarian cancer.

### Claim 28 (depends on 23)

The method of claim 23, wherein the cell is a CAR-T cell.

### Claim at position 27

-30. (canceled)

### Claim 31 (depends on 18)

A method to prevent, inhibit or treat an autoimmune disease is a mammal, comprising administering to the mammal a composition having a plurality of the isolated cell of claim 18.

### Claim at position 29

-33. (canceled)

### Claim 34 (depends on 31)

The method of claim 31, wherein the autoimmune disease is multiple sclerosis.

### Claim at position 31

-36. (canceled)
